Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial
Source: View publication →
The SNAP trial demonstrated that benzylpenicillin halved the risk of acute kidney injury and showed a high probability of non-inferiority for mortality compared to flucloxacillin or cloxacillin in adults with penicillin-susceptible Staphylococcus aureus bacteraemia.
Key Findings
Study Design
Study Limitations
Clinical Significance
Although the strict prespecified non-inferiority criterion for mortality was not formally met due to early trial closure, the highly probable comparable efficacy—combined with a halved risk of acute kidney injury—positions benzylpenicillin as the preferred and safer therapy over flucloxacillin or cloxacillin for adults with penicillin-susceptible S. aureus (PSSA) bacteraemia.
Historical Context
For decades, the vast majority of S. aureus isolates produced beta-lactamase, rendering them resistant to native penicillin. Consequently, anti-staphylococcal penicillins (e.g., flucloxacillin, cloxacillin, nafcillin) became the empiric and definitive standard of care. Recently, however, penicillin-susceptible S. aureus (PSSA) has re-emerged globally, accounting for up to 25% of S. aureus bacteraemia isolates in some regions. With the advent of reliable phenotypic susceptibility testing, clinicians sought to return to native benzylpenicillin due to its theoretically superior pharmacokinetic profile and lower expected nephrotoxicity. The platform SNAP trial was designed to replace historical empiricism with rigorous evidence for exactly these types of critical S. aureus infections.
Guided Discussion
High-yield insights from every perspective
What is the difference in mechanism and spectrum between benzylpenicillin and flucloxacillin, and why might flucloxacillin be more nephrotoxic?
Key Response
Both are beta-lactams that inhibit cell wall synthesis. Benzylpenicillin (Penicillin G) is susceptible to beta-lactamase, hence only effective for penicillin-susceptible S. aureus (PSSA). Flucloxacillin is an antistaphylococcal penicillin resistant to staphylococcal beta-lactamase, used for MSSA. Antistaphylococcal penicillins are associated with higher rates of acute interstitial nephritis (AIN) compared to natural penicillins, which explains the higher AKI risk observed in the trial.
When managing a patient with MSSA bacteremia whose isolate is later found to be penicillin-susceptible, how should the SNAP trial findings influence your management regarding organ toxicity?
Key Response
The SNAP trial supports actively de-escalating from flucloxacillin or cloxacillin to benzylpenicillin for PSSA bacteremia. Residents should recognize that de-escalation in this context not only narrows the antimicrobial spectrum but also actively reduces patient harm by halving the risk of acute kidney injury without compromising survival.
How does the historical concern for the 'inoculum effect' and cryptic beta-lactamase production in PSSA isolates influence the interpretation of the SNAP trial's non-inferiority results for mortality?
Key Response
Historically, ID specialists avoided penicillin for PSSA due to the 'inoculum effect' (high bacterial burdens overcoming the drug) and the risk of undetected weak beta-lactamase producers leading to false susceptibility. The high probability of non-inferiority in mortality suggests that modern standard phenotypic testing is sufficient and these theoretical concerns do not translate to worse clinical outcomes in appropriately identified PSSA bacteremia.
Given the clear safety benefit of reduced AKI and non-inferior efficacy, should benzylpenicillin become the standard of care for all PSSA bacteremia, and what logistical barriers exist for implementation?
Key Response
The trial strongly argues for benzylpenicillin as the standard of care for PSSA to prevent nephrotoxicity. However, attendings must navigate operational barriers: many microbiology labs do not routinely test or report penicillin susceptibility for S. aureus, assuming MSSA treatment is sufficient, and benzylpenicillin requires frequent dosing or continuous infusion, complicating outpatient parenteral antimicrobial therapy (OPAT).
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SNAP trial utilized a non-inferiority design for mortality. How does the choice of the non-inferiority margin and the intention-to-treat versus per-protocol analysis impact the validity of the conclusions?
Key Response
In non-inferiority trials, setting an appropriately narrow margin is critical to avoid accepting an inferior treatment. Furthermore, unlike superiority trials where intention-to-treat (ITT) is conservative, ITT in non-inferiority trials can bias results toward the null (non-inferiority) due to non-adherence or crossovers. A rigorous critique must verify that both ITT and per-protocol analyses demonstrate non-inferiority to ensure the mortality claim is robust.
As a peer reviewer, how do you critically evaluate the open-label nature of this trial when assessing the secondary endpoint of acute kidney injury (AKI)?
Key Response
While mortality is a hard, objective endpoint, AKI is subject to diagnostic and surveillance bias. In an open-label trial, clinicians aware that a patient is on a potentially nephrotoxic drug (flucloxacillin) might check serum creatinine more frequently or manage fluids differently, potentially skewing AKI detection rates. Reviewers must scrutinize the protocol's standardization of lab draws to ensure the AKI difference is a true pharmacological effect.
Current IDSA and ESCMID guidelines for S. aureus bacteremia focus on antistaphylococcal penicillins or cefazolin for MSSA. How should the SNAP trial data shift the GRADE recommendations for PSSA specifically?
Key Response
Current guidelines mention penicillin for PSSA but lack strong RCT evidence advocating its active use over antistaphylococcal penicillins. The SNAP trial provides high-quality (Level 1) evidence that de-escalation to benzylpenicillin reduces AKI by 50% without compromising efficacy. Guidelines should be updated with a strong recommendation for routine penicillin susceptibility testing in MSSA and subsequent de-escalation to benzylpenicillin to minimize drug-induced nephrotoxicity.
Clinical Landscape
Noteworthy Related Trials
ARREST Trial
Tested
Adjunctive rifampicin alongside standard antibiotic therapy
Population
Adults with Staphylococcus aureus bacteraemia
Comparator
Standard antibiotic therapy plus placebo
Endpoint
Bacteriologically confirmed treatment failure, recurrence, or death within 12 weeks
CAMERA2 Trial
Tested
Standard MRSA therapy plus an antistaphylococcal beta-lactam (e.g., flucloxacillin)
Population
Adults with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia
Comparator
Standard MRSA therapy (vancomycin or daptomycin) alone
Endpoint
Composite of mortality, persistent bacteremia, relapse, or treatment failure at 90 days
SABATO Trial
Tested
Early switch to oral antimicrobial therapy after 5 to 7 days of intravenous treatment
Population
Patients with low-risk Staphylococcus aureus bloodstream infection
Comparator
Standard continuous intravenous therapy
Endpoint
Composite of SAB-related complications or death within 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis